ID: ALA2426283

Max Phase: Preclinical

Molecular Formula: C21H16ClN5O

Molecular Weight: 389.85

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=CC(=O)Nc1ccc(Nc2ncc(Cl)c(-c3c[nH]c4ccccc34)n2)cc1

Standard InChI:  InChI=1S/C21H16ClN5O/c1-2-19(28)25-13-7-9-14(10-8-13)26-21-24-12-17(22)20(27-21)16-11-23-18-6-4-3-5-15(16)18/h2-12,23H,1H2,(H,25,28)(H,24,26,27)

Standard InChI Key:  HIDQBJIUUMDHMC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.85

Molecular Weight (Monoisotopic): 389.1043

AlogP: 5.15

#Rotatable Bonds: 5

Polar Surface Area: 82.70

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.25

CX Basic pKa: 1.10

CX LogP: 4.90

CX LogD: 4.90

Aromatic Rings: 4

Heavy Atoms: 28

QED Weighted: 0.41

Np Likeness Score: -0.93

References

1. Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ..  (2013)  Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).,  56  (17): [PMID:23930994] [10.1021/jm400822z]

Source

Source(1):

• Scientific Literature